Merck raised its adjusted profit outlook after topping third-quarter estimates, driven by stronger-than-expected sales of its immunotherapy Keytruda, including the newer injectable form, Keytruda Qlex.

The company now expects adjusted earnings of $2.77 to $2.82 per share. That is up from its previous range of $2.66 to $2.76 per share. The new guidance includes a one-time charge of $400 million, or 12 cents per share, tied to a licensing agreement with the Chinese cancer drugmaker SciBrunch.

Merck also narrowed the low end of its 2026 revenue guidance to $66.8 billion to $67.3 billion, up from $66.3 billion to $67.3 billion.

Keytruda brought in $8.60 billion in sales for the quarter, above the $7.73 billion analysts expected, according to StreetAccount. Qlex contributed $830 million, the highest quarterly figure since its 2025 launch. Analysts had expected $649 million.

Merck reported net income of $5.07 billion, or $2.04 per share, compared with $5.79 billion, or $2.32 per share, a year earlier. Excluding acquisition and restructuring costs, the company earned $2.49 per share. Revenue rose 5% from a year earlier to $18.09 billion.

Other products also grew. Winrevair, which treats a rare, deadly lung condition, generated $694 million, up 93% from a year earlier and above the $645 million analysts expected. Gardasil, the HPV vaccine, drew about $2 billion on higher U.S. demand, beating the $1.76 billion estimate. Merck's animal health business posted $1.68 billion, slightly below analyst estimates.

The company faces generic competition for Keytruda after key patents begin expiring in 2028. Merck has pursued a series of deals and is positioning Qlex to retain patients as the original intravenous version loses exclusivity.